Samarra J. Pure Appl. Sci., 2020; 2 (3): 1-6
Zeyad Kh. et al.
Samarra Journal of Pure and Applied Science
ISSN:2663-7405
www.sjpas.com
مستوى هرمون انبربتَه مع بعض انمؤشرات انكَموحَوٍة نذى مرضي انسكرً مه انىوع
انثاوٌ فٌ مذٍىة سامراء
زٍاد خانذ انسامرائٌ ،* 1عثمان رشَذ
انسامرائٌ2
-1لغُ اٌى١ّ١بء ،وٍ١خ اٌزشث١خ ،خبِؼخ عبِشاء ،اٌؼشاق )(ziadchemist89@gmail.com
-2لغُ اٌى١ّ١بء اٌزطج١م١خ ،وٍ١خ اٌؼٍ َٛاٌزطج١م١خ ،خبِؼخ عبِشاء ،اٌؼشاق )(othmansamarrai@gmail.com
اٌجحث ِغزً ِٓ سعبٌخ ِبخغز١ش اٌجبحث االٚي
معهومات انبحث:
انخالصة:
رأس٠خ االعزالَ2121/13/17 :
رأس٠خ اٌمجـــٛي2121/14/15 :
رعّٕذ اٌذساعخ ل١بط ِغز٘ ٜٛشِ ْٛاٌجشثزِ ٓ١غ ثؼط اٌّؤششاد
اٌىّٛ١ح٠ٛ١خ فِ ٟصً ِشظ ٝاٌغىش ِٓ ٞإٌٛع اٌثبٔ ،ٟار شٍّذ اٌذساعخ
( )60ػٕ١خ ِٓ ِشظ ٝاٌغىش ِٓ ٞإٌٛع اٌثبٔ ٟرشاٚحذ اػّبسُ٘ ِب ثٓ١
( )73-45عٕخٚ ،وزٌه ( )40ػٕ١خ ألشخبص أصحبء رشاٚحذ اػّبسُ٘ ِب ثٓ١
( )70-40عٕخ اػزجشد وّدّٛػخ ظبثطخ .أٚظحذ إٌزبئح ٚخٛد اسرفبع
ِؼٕ ٞٛػٕذ ِغز ٜٛاحزّبٌ١خ ( )p≤0.05فِ ٟغز ٜٛاٌجشثز ٓ١ػٕذ ِشظٝ
اٌغىش ِٓ ٞإٌٛع اٌثبِٔ ٟمبسٔخ ثبألصحبء ،ار وبْ ِؼذي ِغز ٜٛاٌجشثز ٓ١فٟ
أِصبي اٌّشظِ )263843±178831 ng/ml( ٝمبسٔخ ثبألصحبء ٚاٌز ٞثٍغ
ِغزٛاٖ ( )86846±15887 ng/mlوزٌه أظٙشد ٔزبئح اٌذساعخ اسرفبػب ً
ِؼٕ٠ٛبً فِ ٟغز ٜٛاٌىٍٛوٛص إر وبْ ِؼذي ِغز ٜٛاٌىٍٛوٛص ٌٍّشظ( ٝ
ِ )245.7 ± 43.5 mg/dLمبسٔخ ثبألصحبء ٚاٌز ٞثٍغ ِغزٛاٖ )mg/dl
ٚ ) 89.9 ± 9.7أظٙشد إٌزبئح اسرفبػب ً ِؼٕ٠ٛبً ف ٟرشو١ض ٞأ ٟٔٛ٠اٌصٛدَٛ٠
ٚاٌجٛربعٌ َٛ١ذ ٜاٌّشظٚ )1618431 ± 348168 mmol/L) ٝ
) )5877 ± 1891 mmol/Lػٍ ٝاٌزٛاٌِ ،ٟمبسٔخ ِغ ِدّٛػـخ األصحـبء
ٚاٌز ٞثٍغ رشو١ض ٞاالmmol/L( ٚ )1458241±19885 mmol/L( ٓ١ٔٛ٠
) 3886±1868ػٍ ٝاٌزٛاٌ ٟثّٕ١ب أخفط ِغز ٜٛاٌىٍٛربثٌ ْٛ١ذ ٜاٌّشظٝ
(ِ )18192± 18171 μmol/lمبسٔخ ِغ ِغزٛاٖ ٌذ ٜاالصحبء ٚاٌز ٞثٍغ
( )18379± 18147μmol/lثّٕ١ب اسرفغ ِغز ٜٛاٌّبٌ ْٛثٕبئ ٟاالٌذٙ٠ب٠ذ ٌذٜ
اٌّشظِ )58111±28833 μmol/l( ٝمبسٔخ ثبألصحبء (18762 μmol/l
.)18115 ±
انكهمات انمفتاحَة:
٘شِ ْٛاٌجشثزِ ،ٓ١شض اٌغىش،ٞ
ا ْٛ٠اٌصٛد ،َٛ٠ا ْٛ٠اٌجٛربع،َٛ١
اٌىٍٛربثِ ،ْٛ١بٌ ْٛثٕبئ ٟاالٌذٙ٠ب٠ذ
انمقذمة:
ِشض اٌغىش ٛ٘ Diabetes Miletus ٞاظطشاة اعزمالث ٟغ١ش ِزدبٔظ ٠زّ١ض ثٛخٛد اسرفبع اٌغىش ف ٟاٌذَ ثغجت
ظؼف ف ٟإفشاص األٔغ ٓ١ٌٛأ ٚخًٍ ف ٟػًّ األٔغ ٓ١ٌٛأ ٚوٍّٙ١ب٠ .شرجػ اسرفبع اٌغىش اٌّضِٓ ثّعبػفبد ػذح ِٕٙب اِشاض
األٚػ١خ اٌذِ٠ٛخ Vascular Diseasesػٍ ٝاٌّذ ٜاٌطٔ ً٠ٛغج١ب اٌز ٟرؤثش ػٍ ٝاٌؼٚ ٓ١ٕ١اٌىٍٚ ٝاألػصبة ٚوزٌه ص٠بدح خطش
اإلصبثخ ثأِشاض اٌمٍت ٚاألٚػ١خ اٌذِ٠ٛخ Cardiovascular Diseasesح١ث رغزٕذ اٌّؼب١٠ش اٌزشخ١ص١خ ٌّشض اٌغىش ٞإٌٝ
ػزجبد عىش اٌذَ اٌّشرجطخ ثّشض األٚػ١خ اٌذِ٠ٛخ اٌذل١مخ ٚال عّ١ب اػزالي اٌشجى١خ [.]1
٠صٕف اٌغىش ٞعش٠ش٠ب ً اٌٛٔ ٝػ ٓ١اعبع :ٓ١١إٌٛع االٚي ٛ٘ٚاٌغىش ٞاٌّؼزّذ ػٍ ٝاالٔغInsulin Dependent ٓ١ٌٛ
) ،Diabetes Mellitus (IDDMاِب إٌٛع اٌثبٔ ٟف ٛٙاٌغىش ٞغ١ش اٌّؼزّذ ػٍ ٝاالٔغNon-Insulin Dependent ٓ١ٌٛ
)٘ .]2[ Diabetes Mellitus (NIDDMشِ ْٛاٌجشثز ٛ٘ Preptin ٓ١ثجز١ذ ِى 34 ِٓ ْٛحبِط أِ٠ ٟٕ١زطبثك ِغ ػبًِ
1
إٌّ ٛاٌشج ٗ١ثبالٔغ Insulin-like growth factor ٓ١ٌٛػٕذ ِٛلغ اٌحبِع ٓ١١االِٛ٠ .Leu102 ٚ Asp69 ٓ١١ٕ١خذ اٌجشثز ٓ١فٟ
حج١جبد خال٠ب ث١زب اٌجٕىش٠بع١خ٠ٚ ،زُ إفشاصٖ ِغ األٔغ ٓ١ٌٛاعزدبثخ ٌٍىٍٛوٛصٚ ،لذ أظٙشد اٌذساعبد اٌحذ٠ثخ أْ اٌجشثز٠ ٓ١ؼضص إفشاص
األٔغٌ ٓ١ٌٛذ ٜاٌفئشاْ [ٚ ،]3اْ ٕ٘بن ػاللخ ِحزٍّخ ث٘ ٓ١شِ ْٛاٌجشثزِٚ ٓ١مبِٚخ األٔغٌ Insulin Resistance ٓ١ٌٛذٜ
اٌجشش[ٌ ،]4زا ٘ذفذ اٌذساعخ اٌ ٝرمِ ُ١١غز٘ ٜٛشِ ْٛاٌجشثزٌ ٓ١ذِ ٜشظ ٝاٌغىش ِٓ ٞإٌٛع اٌثبٔ.ٟ
انمواد وطرائق انعمم
خّؼذ 61ػٕ١خ دَ ِٓ اشخبص ِصبث ٓ١ثّشض اٌغىش ِٓ ٞإٌٛع اٌثبٔ ٟرشاٚحذ اػّبسُ٘ ِب ث 73 -45 ٓ١عٕخ 41 ٚ
ػٕ١خ دَ ِٓ اشخبص ػذٚا اصحبء ظب٘ش٠ب ( اػزجشٚا ِدّٛػخ ظبثطخ ) رشاٚحذ اػّبسُ٘ ِب ث 70 -40 ٓ١عٕخ ِٓ اٌّشاخؼٓ١
ٌّغزشف ٝعبِشاء اٌؼبَ ٚاٌّخزجشاد اٌخبسخ١خ فِ ٟذٕ٠خ عبِشاء ِٓ ثذا٠خ شجبغ إٌِ ٝزصف ٔ١غبْ ِٓ اٌؼبَ . 2019ح١ث عحت
ِٓ 5 mlاٌذَ اٌٛس٠ذ ٞثٛعبغخ ِحمٕخ غج١خٚٚ ،ظغ اٌذَ ف ٟأبث١ت اخزجبسٚ ،رشن ٌّذح 10دلبئك ف ٟدسخخ حشاسح اٌّخزجش
ٌ١زخثش ،ثؼذ٘ب فصً اٌّصً ف ٟخٙبص اٌطشد اٌّشوضٌّ ٞذح 10دلبئك ٚثغشػخ 3000دٚسح/دل١مخ ٚحفع ػٕذ دسخخ حشاسح
ٌ -20°Cح ٓ١اخشاء اٌفحٛصبد .لذسد ِغز٠ٛبد ٘شِ ْٛاٌجشثز ٓ١ثبعزخذاَ رمٕ١خ األٌ١ضا ،اِب ِغز٠ٛبد اٌىٍٛوٛص ،ا ْٛ٠اٌصٛدَٛ٠
،Na+ا ْٛ٠اٌجٛربع ،K+ َٛ١اٌىٍٛربث ،(Glutathione-GSH( ْٛ١اٌّبٌ ْٛثٕبئ ٟاالٌذٙ٠ب٠ذ )(Malon dialdehyde-MDA
فمذ لذسد ثبالػزّبد ػٍ ٝاٌطش٠مخ اٌٍ١ٔٛخ ٚحغت غش٠مخ اٌؼًّ اٌّشفمخ ِغ ػذح اٌزحٍ ً١اٌدب٘ضحٚ .رُ اخشاء اٌزحٍ ً١االحصبئٟ
ٌٍج١بٔبد ثبالػزّبد ػٍ ٝاخزجبس ٚ T-testاالٔحشاف اٌّؼ١بس.]5[ Standard deviations(S.D) ٞ
انىتائج
أظٙشد إٌزبئح اسرفبػبً ِؼٕ٠ٛب ً ػٕذ ِغز ٜٛاحزّبٌ١خ ) )p≤1815فِ ٟغز٘ ٜٛشِ ْٛاٌجشثزٚ ٓ١عىش اٌذَ ػٕذ اٌّشظٝ
ِمبسٔخ ثبألصحبء ٚوّب ِٛظح ف ٟاٌدذٚي ٚ 1اٌشىً .1
جذول ِ :1غز ٜٛوً ِٓ ٘شِ ْٛاٌجشثزٚ ٓ١عىش اٌذَ ٌٍّشظِ ٝمبسٔخ ثبألصحبء
)Glucose (mg/dL
)Preptin (ng/ml
انعَىات
األصحبء
89.9 ± 9.73
اٌّشظٝ
245.7 ±43.5
P value
≤ 1815
≤ 1815
300
245.7
250
البربتين (مرضى)
200
البربتين (األصحاء)
150
الكلوكوز (المرضى)
الكلوكوز (األصحاء)
89.9
86.46
100
50
Maen of Preptin level ng/ml and Blood
Sugar mg/dl
263.43
0
شكم ِ :1غز٘ ٜٛشِ ْٛاٌجشثزٚ ٓ١عىش اٌذَ ٌٍّشظِ ٝمبسٔخ ثبألصحبء
ٌٛٚحع وزٌه اسرفبع ِؼٕ ٞٛػٕذ ِغز ٜٛاحزّبٌ١خ ) ) p≤0.05فِ ٟغز ٜٛوً ِٓ ٌ K+ٚ Na+ذ ٜاٌّشظِ ٝمبسٔخ
ثبألصحبء وّب ف ٟاٌدذٚي ٚ 2اٌشىً .2
2
خذٚي ِ :2زٛعػ رشو١ض أ ٟٔٛ٠اٌصٛدٚ َٛ٠اٌجٛربعٌٍّ َٛ١شظِ ٝمبسٔخ ثبألصحبء
)K+ (mmol/L
)Na+ (mmol/L
انعَىات
األصحبء
اٌّشظٝ
≤0.05
≤0.05
P value
180
161.43
160
140
الصوديوم (مرضى)
120
الصوديوم (األصحاء)
100
البوتاسيوم (مرضى)
80
البوتاسيوم (األصحاء)
60
40
20
5.77
3.86
Maen of K+ and Na+ level mmol/L
145.24
0
شكم ِ :2زٛعػ ِغز ٜٛأ ٟٔٛ٠اٌصٛدٚ َٛ٠اٌجٛربعٌٍّ َٛ١شظِ ٝمبسٔخ ثبألصحبء
أشبسد إٌزبئح اٌ ٝأخفبض ِؼٕ ٞٛػٕذ ِغز ٜٛاحزّبٌ١خ p≤0.05فِ ٟغزٌ GSH ٜٛذ ٜاٌّشظِ ٝمبسٔخ ِغ األصحبء،
ف ٟح ٓ١اسرفغ ِؼٕ٠ٛب ِغزٌ MDA ٜٛذ ٜاٌّشظِ ٝمبسٔخ ثبألصحبء ٚوّب ِج ٓ١ف ٟاٌدذٚي ٚ 3اٌشىٍ.4ٚ 3 ٓ١
جذول ِ :3زٛعػ رشو١ض MDA ٚ GSHف ٟأِصبي دَ ِشظ ٝاٌغىشٚ ٞاألصحبء
انعَىات
)MDA (μmol/l
)GSH( μmol/l
األصحبء
1.115 ± 0.762
0.379 ± 0.147
اٌّشظٝ
5.110 ± 2.833
0.192 ± 0.070
≤0.05
≤0.05
P value
0.379
0.4
0.3
0.25
المرضى
0.192
األصحاء
0.2
0.15
0.1
0.05
0
3
Maen of GSH level μmol/l
0.35
شكم ِ :3زٛعػ ِغز ٜٛاٌىٍٛربثٌٍّ ْٛ١شظِ ٝمبسٔخ ثبألصحبء
6
5.11
4
المرضى
3
األصحاء
2
1.11
1
Maen of MDA level μmol/l
5
0
شكم ِ :4زٛعػ ِغز ٜٛاٌّبٌ ْٛثٕبئ ٟاألٌذ٘١ذ ٌٍّشظِ ٝمبسٔخ ثبألصحبء
انمىاقشة:
أشبسد ٔزبئح اٌذساعخ اٌٚ ٝخٛد اسرفبع ِؼٕ ٞٛفِ ٟغز ٜٛاٌجشثز ٓ١فِ ٟصً دَ ِشظ ٝاٌغىش ٞإٌٛع اٌثبٔ ٟوّب ٘ٛ
ِٛظح ف ٟاٌدذٚي ٚ 1اٌشىً ٚ ،1لذ ٠ؼض ٜاٌغجت ف ٟرٌه اٌ ٝأْ اٌجشثز٠ ٓ١ؼًّ ػٍ ٝرحغ ٓ١افشاص االٔغ ٓ١ٌٛثٛعبغخ اٌىٍٛوٛص
[ ،]6ار ٠ؼذ ٘شِ ْٛاٌجشثزِ ٓ١حفِّضاً إلفشاص األٔغ ٓ١ٌٛثٛعبغخ اٌىٍٛوٛص [ٚ ]7ارفمذ ٘زٖ إٌز١دخ ِغ ِب رٛصٍذ اٌ ٗ١دساعبد عبثمخ
[ٚ .]8،4ثٕ١ذ ٔزبئح اٌذساعخ اسرفبػب ً ِؼٕ٠ٛب ً فِ ٟغز ٜٛاٌىٍٛوٛص ٌذِ ٜشظ ٝاٌغىش ِٓ ٞإٌٛع اٌثبِٔ ٟمبسٔخ ثبألصحبء ار ٠ؼذ
اسرفبع اٌىٍٛوٛص ػالِخ ػٍ ٝاالصبثخ ثبٌغىش٘ٚ ٞزا ٠زفك ِغ دساعبد اخش ٜاٌز ٟثٕ١ذ اْ اٌغجت ف ٟص٠بدح رشو١ض اٌىٍٛوٛص فٟ
اٌذَ لذ ٠شخغ اٌ ٝص٠بدح ِمبِٚخ ِغزمجالد اٌخال٠ب اٌّغزد١جخ ٌألٔغٚ ٓ١ٌٛاٌز٠ ٞؤد ٞاٌ ٝظؼف حًّ االٔغٌٍ ٓ١ٌٛىٍٛوٛص اٌ ٝداخً
اٌخال٠ب ِّب ٠ؤد ٞاٌ ٝرشاوّٗ ف ٟاٌذَ [.]9
وزٌه أظٙشد إٌزبئح اسرفبػب ً ِؼٕ٠ٛب ػٕذ p≤1815فِ ٟغزٌ K+ ٜٛذ ٜاٌّشظِ ٝمبسٔخ ِغ األصحبء وّب ِ٘ٛ ٛظح فٟ
اٌدذٚي ٚ 2اٌشىً ٚ ،2لذ أشبسد ثؼط اٌذساعبد اٌ ٝأْ ِشظ ٝاٌغىش٠ ٞظٙش ٌذ ُٙ٠اسرفبع غف١ف فِ ٟغزِ K+ٜٛمبسٔخ
ثّغزٛاٖ ٌذ ٜاألصحبء ثغجت دٚس األٔغ ٓ١ٌٛاٌز٠ ٞؼضص رذفك K+ف ٟاٌؼعالد اٌ١ٙىٍ١خ ٚاٌخال٠ب اٌىجذ٠خ ِّب ٠ض٠ذ ِٓ ٔشبغ ِعخخ
اٌصٛد/ َٛ٠اٌجٛربع َٛ١ادٕٛ٠ع ٓ١ثالث ٟاٌفٛعف١ذ Sodium/Potassium Adenosin Triphosphatase (Na+/K+-
.
)]11،11[ ATPase
٠ظٙش ا٠عب ِٓ خالي اٌدذٚي ٚ 2اٌشىً 2اسرفبع فِ ٟغزٌ Na+ ٜٛذ ٜاٌّشظِ ٝمبسٔخ ِغ األصحبء ّ٠ٚىٓ اْ ٠فغش رٌه
ثئْ ِشظ ٝاٌغىش٠ ٞؼبٔ ْٛثشىً ِغزّش ِٓ رغ١ش ف ٟرشو١ضٚ Na+رٌه ٠ؼىظ اٌزٛاصْ ث ٓ١حشوخ اٌّ١بٖ إٌبردخ ػٓ اسرفبع
اٌىٍٛوٛص ف ٟاٌذَ خبسج اٌخال٠ب اٌز ٟرخفط رشو١ض ٘زا اال ْٛ٠ف ٟاالدساس االعّٛص ٞإٌبخُ ػٓ اٌىٍٛوٛص ٚاٌز ً١ّ٠ ٞاٌ ٝسفغ
ِغز ٜٛاٌصٛد٠ٚ .]12[َٛ٠ظٙش اٌدذٚي ٚ 3اٌشىً 3أخفبض ِؼٕ ٞٛفِ ٟغزٌ GSH ٜٛذ ٜاٌّشظِ ٝمبسٔخ ِغ األصحبء
ٌٚؼً عجت ٘زا االٔخفبض ٠ؼٛد اٌ ٝرشاوُ اٌدزٚس اٌحشح ثغجت اإلخٙبد اٌزأوغذ ، ٞإر رى ْٛعشػخ إٔزبخٙب أوجش ِٓ عشػخ رح١١ذ٘ب
ثأِبْ ثٛعبغخ آٌ١بد اٌذفبع اٌّعبدح ٌألوغذح ف ٟاٌدغُ اٌح ٟوبألٔظّخ غ١ش األٔض١ّ٠خ اٌّعبدح ٌألوغذح ِثً ٠ٚ ]13[ GSHحث
اٌغىش ٞرغ١شاد فٔ ٟشبغ إٔضّ٠بد GSHاٌّخزضي اٌزّ٠ ٟىٓ أْ رؼطً عٍغٍخ رفبػالد اٌدزٚس اٌحشحٚ ،إْ أ ٞرغ١١ش فٟ
ِغز٠ٛبرٙب ع١دؼً اٌخال٠ب ػشظخ ٌٍزأوغذ ٚثبٌزبٌ ٟإصبثخ اٌخٍ١خ ثبإلخٙبد اٌزأوغذ ،]14[ ٞأِب ِغز MDA ٜٛفمذ أظٙش إسرفبػبً
ٌذ ٜاٌّشظِ ٝمبسٔخ ثبألصحبء وّب ِ٘ٛ ٛظح ف ٟاٌدذٚي ٚ 3اٌشىً ّ٠ٚ 3ىٓ أْ ٠ؼض ٜاٌغجت إٌ ٝص٠بدح آٌ١بد اإلخٙبد اٌزأوغذٞ
اٌز٠ ٟغججٙب ثشىً أعبط اسرفبع ِغز ٜٛاٌىٍٛوٛص اٌّضِٓ ٚاٌز٠ ٞؼذ عّخ ِٓ عّبد ِشض اٌغىش.]15[ ٞ
4
References
1. Yang, G., Li, L., Chen, W., Liu, H., Boden, G., & Li, K. (2009). Circulating preptin levels in
normal, impaired glucose tolerance, and type 2 diabetic subjects. Annals of
medicine, 41(1), 52-56.
2. Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Hebrok, M., Herold, K. C., Accili, D., ... &
Rhodes, C8 J8 (2111)8 How does type 1 diabetes develop?: the notion of homicide or βcell suicide revisited. Diabetes, 60(5), 1370-1379.
3. BUCHANAN, C. M., PHILLIPS, A. R., & COOPER, G. J. (2001). Preptin derived from
proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet β-cells and
enhances insulin secretion. Biochemical Journal, 360(2), 431-439.
4. Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987).
Purification and characterization of a peptide from amyloid-rich pancreases of type 2
diabetic patients. Proceedings of the National Academy of Sciences, 84(23), 8628-8632.
5. El-Eshmawy, M., & Abdel Aal, I. (2015). Relationships between preptin and osteocalcin
in obese, overweight, and normal weight adults. Applied Physiology, Nutrition, and
Metabolism, 40(3), 218-222.
6. Kalayci, M., Halifeoglu, I., Kalayci, H., Ugur, K., & Yilmaz, M. (2019). Plasma preptin
levels in patients with type 2 diabetes mellitus. International Journal of Medical
Biochemistry 2(1), 1-5.
7. Solis-Herrera, C., Triplitt, C. L., & Lynch, J. L. (2014). Nephropathy in youth and young
adults with type 2 diabetes. Current diabetes reports, 14(2), 456.
8. Karalliedde, J., & Gnudi, L. (2016). Diabetes mellitus, a complex and heterogeneous
disease, and the role of insulin resistance as a determinant of diabetic kidney
disease. Nephrology dialysis transplantation, 31(2), 206-213.
9. Abbed, A. M. (2019). Effect of Metformin and Glimepiride Treatment on Some
Biochemical Parameters in Diabetic Male Patients with Chronic Renal Failure. Ibn ALHaitham Journal For Pure and Applied Science, 32(2), 38-44.
10. Ali, A. A. (2010). The Effect of Long Term use of Glibenclamide on Serum and Urinary
Sodium and Potassium Level in Type 2 DM Patients. Iraqi Journal of Pharmaceutical
Sciences (P-ISSN: 1683-3597, E-ISSN: 2521-3512), 19(1), 58-61.
11. Datchinamoorthi, S., Vanaja, R., & Rajagopalan, B. (2016). Evaluation of serum
electrolytes in type II diabetes mellitus. Int J Pharm Sci Rev Res, 40(1), 251-253.
12. Ilochi, O. N., Chuemere, A. N., & Olorunfemi, O. J. (2018). Evaluation of
antihyperglycaemic potential of Allium cepa, coffee and oxidative stress. International
Journal of Biochemistry and Physiology, 3-1.
13. Asmat, U., Abad, K., & Ismail, K. (2016). Diabetes mellitus and oxidative stress—A
concise review. Saudi pharmaceutical journal, 24(5), 547-553.
14. Incerti, J., Zelmanovitz, T., Camargo, J. L., Gross, J. L., & de Azevedo, M. J. (2005).
Evaluation of tests for microalbuminuria screening in patients with
diabetes. Nephrology Dialysis Transplantation, 20(11), 2402-2407.
5
Samarra J. Pure Appl. Sci., 2020; 2 (3): 1-6
Zeyad Kh. et al.
Samarra Journal of Pure and Applied Science
www.sjpas.com
ISSN:2663-7405
Preptin hormone level and some biochemical parameters in type
2 diabetic patients in Samarra city
Zeyad Khaled Al-Samarrai 1*, Othman Rashid Al Samarrai 2
1- Department of Chemistry, College of Education, University of Samarra (ziadchemist89@gmail.com)
2- Applied Chemistry Department, College of Applied Science, University of Samarra (othmansamarrai@gmail.com)
Article Information
Abstract
Received: 17/03/2020
Accepted: 15/04/2020
The study included evaluation of preptin level and some biochemical
parameters in sera of type 2 diabetes patients. The study included (60)
samples of type 2 diabetes patients with age ranged between (45-73)
years old, as well as (40) of blood samples of apperently healthy
individuals as control with ages ranged between (40-70) years old. The
results showed a significant increase at (p ≤0.05) in perpetin level of
patients (263.43±178.31 ng/ml) compared with control (86.46 ±15.87
ng/ml). Glucose level showed a significant increase at (p ≤1815) in
patients group (245.7 ± 43.5mg/dL) compared with control (89.9 ± 9.7
mg/dL). The results also indicates a significant increase at (p ≤1815) in
sodium and potassium ions levels (161.431± 34.168 and 5.77± 1.90
mmol/L) respectively in patients compared with control (145.241±
19.85 and 3.86± 0.68 mmol/L) respectively. The level of glutathione
decreased at (p ≤0.05) significantly in sera of diabetes patients (0.192±
0.070 μmol/l) compared with control (0.379± 0.147μmol/l), while malon
dialdehyde level was increased significantly (5.110± 2.833μmol/l) in
patients compared with control (1.115 ± 0.762 μmol/l(
Keywords:
Preptin, Diabetes, Na+, K+,
GSH, MDA.
6